Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
1.290
-0.080 (-5.84%)
Aug 1, 2025, 4:00 PM - Market closed
CTI BioPharma Stock Forecast
CTXR's stock price has decreased by -94.3% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $53, which forecasts a 4,008.53% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $100.
Price Target: $53.00 (+4,008.53%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 30, 2025.
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +365.12% | Jun 30, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 → $6 | Strong Buy | Maintains | $9 → $6 | +365.12% | Jun 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +597.67% | Jun 9, 2025 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 23, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +597.67% | May 15, 2025 |
Financial Forecast
Revenue This Year
15.99M
Revenue Next Year
74.50M
from 15.99M
Increased by 365.90%
EPS This Year
-3.33
from -5.97
EPS Next Year
1.39
from -3.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.8M | 82.2M | 183.8M | ||
| Avg | 16.0M | 74.5M | 162.6M | ||
| Low | 15.0M | 66.4M | 140.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 414.1% | 146.7% | ||
| Avg | - | 365.9% | 118.3% | ||
| Low | - | 315.4% | 89.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.42 | 3.52 | 4.90 | ||
| Avg | -3.33 | 1.39 | 3.09 | ||
| Low | -3.19 | -0.61 | 1.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 252.2% | ||
| Avg | - | - | 122.0% | ||
| Low | - | - | -2.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.